Prostate Cancer
Conditions
Keywords
Primary, Prostate, Cancer, Primary T1c/T2a organ confined prostate cancer, organ-confined
Brief summary
This study will compare high intensity focused ultrasound to standard brachytherapy in the treatment of primary, organ confined prostate cancer.
Detailed description
The proposed study is a prospective, non-randomized concurrently controlled study. The active treatment arm uses the HIFU procedure with the Sonablate device. The control arm uses the brachytherapy procedure. The safety and effectiveness of the Sonablate arm will be compared with the brachytherapy arm. The control arm of the study will be conducted at clinical sites different from the Sonablate arm.
Interventions
DEVICEHIFU (Sonablate® 500)
High Intensity Focused Ultrasound
DEVICEBrachytherapy
Standard of care
Sponsors
SonaCare Medical
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* T1c or T2a carcinoma of the prostate confirmed by biopsy; * life expectancy of 5(five) years or more; * prostate biopsy with 10(ten) or more core biopsies; * Gleason score of 6(six) or less; * serum Prostate Specific Antigen (PSA) of 10(ten)ng/ml or less; * prostate volume of less than 40(Forty)cc; * distance from the Anterior capsule surface to the Posterior capsule surface (AP Diameter) of 40(Forty)cm or less; * informed consent for the treatment study through 24 months post-treatment follow-up
Exclusion criteria
* men who have had previous definitive treatment for prostate cancer; * evidence of metastatic disease and/or a previous positive bone-scan, previous diagnosis or treatment for cancer within the last 5(five) years; * prior hormonal therapy for prostate cancer (including bilateral orchiectomy); * inability to tolerate a transrectal ultrasound; * active urinary tract infection; * functional bladder problems; * prior significant rectal surgery; * intra-prostatic calcifications greater than 1(One)cm in diameter; * interest in future fertility; * prostatic surgery/procedure (except biopsy) within 1(One) year; * large median lobe of the prostate; * use of medications that can affect PSA within 2(Two) months (e.g. finasteride, saw palmetto); * current bladder cancer, urethral stricture, or bladder neck contracture; * urinary tract and/or rectal fistula; * rectal fibrosis/stenosis; * anomaly of the rectal anatomy or mucus membrane; * prostate seroma/abcess; * prostatitis; * compromised renal function or upper urinary tract disease secondary to urinary obstruction; * bleeding disorders/coagulopathy based on measures of PT and PTT; * implant in the prostate or within 1(One)cm of the prostate; * zip code of the primary residence of the subject is greater than 200(Two hundred) miles from the clinical site or transportation that would hinder the completion of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint will be the absence of biochemical failure, which is defined as a rise of 2.0 ng/mL or more above the PSA nadir and negative biopsy at 24 months. | 24 Months |
Countries
United States
Outcome results
None listed